Logo
x

Search

Subscribe Now

Reduction

Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

  • October 9, 2020
Regeneron's REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

Regeneron's REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

  • September 30, 2020
Novo Nordisk's Ozempic (semaglutide) Receives the US FDA's Approval for Reduction in MACE in Patients with Type 2 Diabetes

Novo Nordisk's Ozempic (semaglutide) Receives the US FDA's Approval for Reduction in MACE in Patients with Type 2 Diabetes

  • January 17, 2020
AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Patients with Type-2 Diabetes

AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Pat...

  • January 6, 2020
Novartis' LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP's Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera

Novartis' LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP's Positive Opinion for Reduction of Kidney...

  • June 7, 2019
Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

  • January 24, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.